REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 8th, 2024 • OnKure Therapeutics, Inc. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of October 4, 2024, by and among Reneo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several investors signatory hereto (each, an “Investor” and collectively, the “Investors”).
ONKURE, INC. EMPLOYMENT AGREEMENTEmployment Agreement • October 8th, 2024 • OnKure Therapeutics, Inc. • Pharmaceutical preparations • Colorado
This Employment Agreement (the “Agreement”) is entered into as of the Effective Date (as defined below) by and among OnKure, Inc. (the “Company”), Reneo Pharmaceuticals, Inc., (which following the Effective Date (as defined below), will be OnKure Therapeutics, Inc.) (“OnKure”) and [NAME] (“Executive”). Certain capitalized terms used in this Agreement are defined in Section 11.
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K. On May 10, 2024, Reneo entered into the Merger Agreement...OnKure Therapeutics, Inc. • October 8th, 2024 • Pharmaceutical preparations
ONKURE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICYOnKure Therapeutics, Inc. • October 8th, 2024 • Pharmaceutical preparations
Reneo Pharmaceuticals, Inc. (which, as of the Closing, as defined in that certain Agreement and Plan of Merger entered into by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC, and OnKure, Inc., dated May 10, 2024, as may be amended from time to time (the “Merger Agreement”) is expected to operate under the name, “OnKure Therapeutics, Inc.”) (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) who are not employees represents an effective tool to attract, retain and reward such Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2024 Equity Incentive Plan, as amended from time to time, or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or similar term in the equity plan then in pla
ONKURE THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 8th, 2024 • OnKure Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [DATE], and is between OnKure Therapeutics, Inc., a Delaware corporation (the “Company”), and [NAME] (“Indemnitee”).
